X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

Molecular Cancer

期刊標題檢索 MOL CANCER 最新評論: The editor-in-chief of MC has many articles written by Chinese people... (2024-10-06)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[Molecular Cancer]您好,您是該頁面的第 318281 位訪客。

期刊簡介
期刊名稱Molecular Cancer Molecular Cancer
LetPub Score
8.5
52 ratings
Rate

Reputation
8.6

Influence
8.3

Speed
8.7

期刊簡稱MOL CANCER
ISSN1476-4598
h-index103
CiteScore
CiteScoreSJRSNIPCiteScore Rank
54.908.2224.737
Subject fieldQuartilesRankPercentile
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Molecular Medicine
Q12 / 178
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Cancer Research
Q13 / 230
Category: Biochemistry, Genetics and Molecular Biology
Subcategory: Oncology
Q17 / 404

自引率 (2023-2024)2.20%自引率趨勢
掲載範囲
Molecular Cancer promotes the exchange of ideas, concepts and findings in any area of cancer and related biomedical science, from a molecular point of view. Molecular Cancer is interested in articles from basic, translational and clinical research, opening new avenues for the understanding, prevention, diagnosis and treatment of cancer. Topics of interest include, but are not limited to: cell and tumor biology, angiogenesis, animal models, metastasis, cancer antigens and the immune response to them, cellular signalling and molecular biology, epidemiology, genetic and molecular profiling of cancer and molecular targets, cancer stem cells, DNA damage and repair, cell cycle, apoptosis, molecular virology and vaccine- and antibody-based cancer therapies.
官方網站http://molecular-cancer.biomedcentral.com
在線稿件提交https://submission.nature.com/new-submission/12943/3
開放訪問Yes
出版商BioMed Central
主題領域医学
出版國/地區ENGLAND
發行頻率月刊
創刊年2002
每年文章數165每年文章數趨勢
黃金OA百分比100.00%
OA Related Info
APC: Yes( EUR3990; USD4890; GBP3490; )
APC waiver:Check Notes
Other charges: No
Keywords: oncology、tumour biology、cancer antigens
Useful LinksAims & ScopeAuthor InstructionsEditorial BoardAnonymous peer review
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
BIOCHEMISTRY & MOLECULAR BIOLOGYSCIEQ14/313
ONCOLOGYSCIEQ110/322
索引 (SCI or SCIE)Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1476-4598%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Average 2 Month(s)
競爭力 *來自作者的數據: About 50%
參考鏈接
相關期刊 【Molecular Cancer】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    NATURE MEDICINEH-index: 497

    CiteScore: 100.90
    CELLH-index: 705

    CiteScore: 110.00
    Molecular PlantH-index: 85

    CiteScore: 37.60
    NUCLEIC ACIDS RESEARCHH-index: 452

    CiteScore: 27.10
    Molecular CellH-index: 356

    CiteScore: 26.00
    PROGRESS IN LIPID RESEARCHH-index: 132

    CiteScore: 24.50
    TRENDS IN MICROBIOLOGYH-index: 172

    CiteScore: 25.30
    CELL DEATH AND DIFFERENTIATIONH-index: 193

    CiteScore: 24.70
    Nature Chemical BiologyH-index: 182

    CiteScore: 23.90
    TRENDS IN MOLECULAR MEDICINEH-index: 160

    CiteScore: 24.60
    學科內最受檢索的期刊 頁面查看次數
    International Journal of Biological Macromolecules1751993
    FASEB JOURNAL724615
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS659025
    NUCLEIC ACIDS RESEARCH555254
    JOURNAL OF BIOLOGICAL CHEMISTRY399558
    International Journal of Biological Sciences309535
    CELL302917
    GENETICS AND MOLECULAR RESEARCH257600
    ONCOGENE237152
    PLANT SCIENCE232200
  •  

    Molecular Cancer Molecular Cancer
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    2    3    4    5    6    7    8    下一頁    末頁  (頁
/40)
  [Molecular Cancer] 的評論撰寫評論
作者: 重阳悦爱


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-29 12:56:35 評論於
Review speed: 3.0 | Submission acceptance rate: 25.0
Focus areas: Oncology
Experience sharing: The journal has started to request original data. To be objective, Molecular Cancer currently has a high rejection rate. Let's give it a try and submit an article now
(0) 讚! | 重阳悦爱

作者: 蒙德青文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-23 08:33:52 評論於
What is the status of the submission, will there be an email notification?
(0) 讚! | 蒙德青文

作者: 凌霄迎波


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-22 18:49:02 評論於
The submission on June 20th was incorrect
(0) 讚! | 凌霄迎波

作者: 凌霄迎波


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-15 13:52:50 評論於
It was reviewed in just one day
(0) 讚! | 凌霄迎波

作者: Nick Peacock


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-13 19:43:54 評論於
Research Focus: Immunology; Tumor; Gene Experience Sharing: Submitted for review on August 14th
(0) 讚! | Nick Peacock

作者: 景焕小姐姐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-12 18:57:10 評論於
Excuse me, do you have any plans behind you?
(0) 讚! | 景焕小姐姐

作者: 景焕小姐姐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-11 22:28:22 評論於
How many days after the editor is assigned will it be reviewed?
(0) 讚! | 景焕小姐姐

作者: 景焕小姐姐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-11 22:26:32 評論於
How is your current status? How long until the second trial?
(0) 讚! | 景焕小姐姐

作者: 景焕小姐姐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-11 22:22:05 評論於
Any progress?
(0) 讚! | 景焕小姐姐

作者: 景焕小姐姐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-11 13:38:21 評論於
Review speed: 6.0
Research focus: Tumor experience sharing
Question for all the comrades who have submitted their manuscripts: How long does it usually take for the editor to make the next decision after being appointed? It has been 4 days now
(0) 讚! | 景焕小姐姐

作者: 景焕小姐姐


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-11 11:01:05 評論於
May I ask when you will submit the draft in the next few days?
(0) 讚! | 景焕小姐姐

作者: 魔都吉星


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-10 22:56:37 評論於
It hasn't been a month yet, right? What's the situation now?
(0) 讚! | 魔都吉星

作者: 凌霄迎波


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-05 22:22:24 評論於
Review speed: 3.0 Experience sharing: Submitted on July 20th, still no updates today, it's been almost two months. Any fellow peers in the same situation? When can we expect revisions?
(0) 讚! | 凌霄迎波

作者: 碧波妙蝶


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-08-05 10:36:51 評論於
Have you made progress to the next step? It's been over two weeks since I submitted my article and still no editor appointed
(0) 讚! | 碧波妙蝶

作者: 凌霄迎波


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-31 11:12:39 評論於
Review speed: 2.0
Research emphasis: circRNA
Tumor experience sharing: Submitted on July 20th, there has been no change today. Are there any buddies in the same situation? When can I revise it?
(0) 讚! | 凌霄迎波

作者: 天神院梦凝


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-07-27 08:29:47 評論於
Looking at the entire development process of IF, this journal is the classic 5-point magazine (=JBC? Not necessarily). For whatever reason, putting low-quality articles or even fake articles in it, this journal cannot be a top journal. Just like the elementary school textbook problem: if there are 10 birds on a tree, and you knock down one with a potato, how many are left? The Impact Factor says there are 9 left, but the professionals have already left
(0) 讚! | 天神院梦凝

作者: 凌霄迎波


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-27 19:55:52 評論於
What does peer review mean? Does it mean that it has been sent for review?
(0) 讚! | 凌霄迎波

作者: 蒙德青文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-14 13:33:21 評論於
Review speed: 1.0 | Submission acceptance rate: 25.0 Weighted research direction: Oncology Experience sharing: Rejected in three days, asked for a revision as a correspondence. Forget it
(0) 讚! | 蒙德青文

作者: 重庆医科大学基础


領域: 医学
審稿時間: 3.0 month(s)
結果: 修改後接受


撰寫評論

2023-04-20 23:13:20 評論於
This journal was included in the warning list by our school before the new year and is not recognized. Four articles were submitted by colleagues in our department, and all of them were accepted. The proportion of Chinese authors is very high, and it is indeed of relatively low quality. It was a waste of time.
(0) 讚! | 重庆医科大学基础

作者: 淡忘


領域: 医学
審稿時間: 1.0 month(s)
結果: 修改後接受


撰寫評論

2023-04-03 20:20:56 評論於
The impact factor has increased, and it seems a bit difficult for Chinese people to publish articles. Finally, I got one this year.
(31) 讚! | 淡忘

作者: 天心来了


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-03-19 20:47:57 評論於
Review speed: 6.0 | Submission acceptance rate: 50.0
Research focus: Tumor microenvironment
Experience sharing: I submitted a review article in December 2022, received major revisions over Chinese New Year, had two weeks to make revisions, added three tables, and made many changes. After a second round of review, two reviewers had no comments, except one suggested changing the title. The article was accepted in mid-March 2023. Overall, the process went smoothly and I consider myself lucky to have my first article accepted as a master's student
(0) 讚! | 天心来了

作者: 天心来了


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-03-19 16:02:57 評論於
I passed my second exam in three weeks
(0) 讚! | 天心来了

作者: Vito Minnie


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-03-12 13:50:24 評論於
I have also read this article, it lacks novelty and depth of research, it is too shallow, just barely reaching a 5-point level, a clichéd ceRNA mechanism
(0) 讚! | Vito Minnie

作者: 魔都小柔


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-13 23:51:53 評論於
molecular cancer, the shrine of frozen time, one year has passed, can't hold onto the spring and autumn, living up to the years and not letting you down
(0) 讚! | 魔都小柔

作者: 魔都小柔


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-13 17:12:16 評論於
First must be the paper, followed by the carrot and then the stick
(0) 讚! | 魔都小柔

首頁    上一頁    2    3    4    5    6    7    8    下一頁    末頁  (頁
/40)

開始撰寫 [Molecular Cancer] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*